The Department of Justice’s recent declination in the Balt Medical matter provides another important data point in understanding how DOJ is applying its updated Corporate Enforcement and Voluntary Self-Disclosure Policy in practice. While declinations are always fact-specific, this letter offers a textbook example of how a company can navigate a significant FCPA issue and still avoid criminal prosecution.

The declination letter, issued to Balt SAS, outlines a straightforward but serious set of facts. According to the government, between approximately 2017 and 2023, Balt paid roughly $602,000 in bribes to a physician at a state-owned hospital in France. The payments were routed through a third-party consultant in Belgium and were intended to influence purchasing decisions for medical devices, including embolization coils. Employees and agents allegedly took steps to conceal the payments, including the use of false invoices and purported “bonus” payments. The scheme generated approximately $1.68 million in revenue and over $1.2 million in profits.

On its face, this is not a marginal case. It involves a multi-year bribery scheme, use of intermediaries, falsified documentation, and clear intent to influence a foreign official—core FCPA misconduct. Yet DOJ declined prosecution. The question, as always, is why.

The answer lies squarely in Balt’s post-misconduct conduct. DOJ specifically grounded its decision in several key factors under the Corporate Enforcement Policy. First, Balt made a timely and voluntary self-disclosure to the DOJ Fraud Section. Notably, the misconduct was identified during an ongoing internal investigation, and the company disclosed while that investigation was still in progress. This is a critical point. DOJ continues to reward companies that come forward early, even before all facts are fully developed.

Second, Balt provided full and proactive cooperation. While the letter does not detail every aspect of cooperation, it emphasizes that Balt provided all relevant information and supported the government’s investigation. Under DOJ policy, this typically includes identifying responsible individuals, preserving and producing documents, and facilitating access to evidence and witnesses. Cooperation is not passive—it requires initiative and transparency.

Third, Balt engaged in timely and appropriate remediation. Although the letter is less detailed on specific remediation measures, DOJ’s reference to remediation indicates that the company took meaningful steps to address the root causes of the misconduct and strengthen its compliance framework. This remains a central requirement under DOJ policy—companies must demonstrate that the misconduct is unlikely to recur.

Finally, DOJ’s analysis reflects the absence—or at least manageable level—of aggravating circumstances. While the conduct was serious, DOJ determined that the company’s response outweighed those concerns. This balancing is critical under the Corporate Enforcement Policy, which allows for declinations even in cases involving significant misconduct where the company’s actions demonstrate genuine accountability.

The financial component of the resolution is also instructive. Balt agreed to disgorge approximately $1.21 million in profits derived from the misconduct. This reinforces a consistent DOJ principle: a declination is not a free pass. Companies must still give up ill-gotten gains and compensate for the benefits derived from wrongdoing.

Equally important, the declination letter makes clear that DOJ’s decision applies only to the company—not to individuals. The government expressly reserves the right to pursue prosecutions against employees, officers, or agents involved in the misconduct. This is consistent with DOJ’s continued emphasis on individual accountability as a cornerstone of corporate enforcement.

So what are the key takeaways for companies and compliance professionals?

First, timing is everything. Balt’s decision to self-disclose during an active internal investigation likely played a decisive role. Waiting until the government is already aware—or about to become aware—can significantly reduce the benefits available under DOJ policy.

Second, cooperation must be real and complete. DOJ continues to expect companies to go beyond minimal compliance and actively assist in building the case, particularly with respect to identifying individuals.

Third, remediation must be credible and demonstrable. Companies need to show that they understand what went wrong and have taken concrete steps to fix it. This includes compliance program enhancements, disciplinary actions, and structural changes.

Fourth, declination does not mean no consequences. Disgorgement, reputational impact, and ongoing cooperation obligations remain significant.

Ultimately, the Balt Medical declination underscores a broader message: DOJ is serious about its incentive structure. Companies that act quickly, cooperate fully, and remediate effectively can achieve meaningful outcomes—even in cases involving substantial misconduct. But those benefits are not automatic. They must be earned through disciplined, transparent, and credible action.

For compliance officers and boards, the lesson is clear. The time to prepare for a potential disclosure decision is not when the issue arises—it is now.